Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (19172)	4/17/1998 1:40:00 PM
From: Henry Niman	Respond to of 32384

Bob, The Droloxifene treatment results were similar to the Tamoxifen results, so PFE changed course and moved away from treatment and towards prevention. The 10K says that Targretin is in Phase II/III trials for breast cancer which is also in the first table in the new annual report. I have not seen any press release on the Phase II/III trial. Bernie had indicated that LGND mentioned the move toward breast cancer (at H&Q?), but I have seen anything in writing. Tagretin and Panretin could be used in conjunction, but Targretin targets the three RXRs while Panretin can activate the three RXRs as well as the three RARs.